Searched for
GLAND PHARMA EBITDA
Cenexi recovery, new product launches and capacity additions power Gland Pharma outlookGland Pharma stock surged to a 52-week high following robust March quarter and full-year results. Its European unit, Cenexi, is improving p...- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Gland Pharma shares jump 11% as Q4 profit soars 97% YoY, co announces Rs 20/share final dividendShares of Gland Pharma rallied on Monday after the company reported a 97% YoY surge in Q4 profit and strong revenue growth, driven by its C...
- Gland Pharma shares rally 6% as brokerages lift ratings, target prices; here's whyGland Pharma shares surged after strong Q1 results and positive commentary from brokerages citing a turnaround at its European unit Cenexi....
- Gland Pharma shares fall over 4% after weak Q3 result, Jefferies target price cutGland Pharma share price: Revenue from operations fell 10% year-on-year to Rs 1,384 crore. EBITDA increased by 1% year-on-year to Rs 360 cr...
- Gland Pharma Q3 net profit rises 7% to Rs 205 croreGland Pharma on Monday reported 7% year-on-year (YoY) rise in net profit to Rs 205 crores in Q3FY25.
- Buy Gland Pharma, target price Rs 1,970: Motilal Oswal SecuritiesMotilal Oswal Securities recommends buying Gland Pharma stock. They predict a target price of Rs 1970. The brokerage expects Gland Pharma's...
- Gland Pharma shares zoom 12% post Q2 results; Kotak upgrades on limited downsideGland Pharma Share Price: Gland Pharma shares rose 12% despite a 15.7% YoY profit decline in Q2. Kotak upgraded the stock to 'Reduce' with ...
- Gland Pharma Q4 Results: Net profit more than doubles to Rs 192.4 croreThe company declared its first-ever post-listing dividend of Rs 20 per equity share for FY24.
- Gland Pharma shares hit 20% lower circuit after disappointing Q4 resultsGland Pharma's stock prices hit a 20% lower circuit on BSE after the firm reported a 72% YoY drop in net profit to Rs 79 crore in Q4FY23 du...
- Gland Pharma net profit down 72% to Rs 79 crore in Q4FY23Gland Pharma on Thursday reported 72% year-on-year (YoY) drop in net profit to Rs 79 crores in Q4FY23 due to production shutdown at one of ...
- Hot Stocks: Gland Pharma, Mirza International and Agro Tech Foods could give 19-30% returnOffices and schools have opened, which creates an incremental demand for shoes and that benefits the shoe manufacturers, the brokerage said...
- Gland Pharma falls 5% after announcing Cenexi Group acquisitionCenexi, along with its subsidiaries, is engaged primarily in the business of Contract Development & Manufacturing Organisation (CDMO) of ph...
- Hot Stocks: Global brokerages on UltraTech Cement, Dalmia Bharat, Eicher Motors and Gland PharmaCLSA maintained a buy rating on Eicher Motors with a target price of Rs 4154. The stock closed at Rs 3363 on 22 August. The company is seei...
- Hot Stocks: Global brokerages on Britannia, TVS Motor, Gland Pharma, HEG and Graphite IndiaJPMorgan maintained its neutral rating on Britannia Industries with a target price of Rs 3,930. The stock closed at Rs 3,692 on 18 August. ...
- Smartkarma Research: APAC Healthcare Series - Top picks are poised for multi-year growthGland Pharma’s near-term focus remains on establishing a strong portfolio of complex injectables. The company is working on development of ...
- Gland Pharma in high demand ahead of listingGland Pharma shares were available at a premium of Rs 20 in the grey market during the offer subscription period between Nov 9 and 11. The ...
- Gland Pharma to leverage Fosun’s strengths for growthBiologics and biosimilar drugs are emerging hotspots, and Gland is arming itself to take a leap in this segment, which is estimated to be t...
- Baxter emerges as frontrunner to buy KKR-backed Gland Pharma for $1.1-1.2 billionHyderabad-headquartered Gland is a leading contract manufacturers of injectables, supplying to pharma majors in India and US like Dr Reddy’...
- Gland Pharma promoters put their 60 per cent stake on the blockPromoters of Hyderabad-based speciality injectable drugs maker Gland Pharma have decided to put their controlling stake on the block.
Load More
